J&J Gains Next-Gen CoStar Stent Through $1.4 Bil. Conor Purchase

Johnson & Johnson hopes that its $1.4 bil. purchase of next-generation drug-eluting stent developer Conor Medsystems will help it retain top-tier market share as a flurry of new competitors joins the market